RHOA抗体;RHOA Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using RHOA mouse mAb against Jurlat (1), MCF-7 (2),A431 (3), and Hela (4) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using RHOA mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using RHOA mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using RHOA mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using RHOA mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of K562 cells using RHOA mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human gastric cancer tissues using RHOA mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human endometrial carcinoma tissues using RHOA mouse mAb with DAB staining.    

  
  

**Background of RHOA Antibodies**

RhoA (Ras homolog family member A) is a small GTPase protein regulating critical cellular processes like cytoskeleton dynamics, cell migration, proliferation, and gene expression. Dysregulation of RhoA signaling is implicated in cancer, autoimmune disorders, and cardiovascular diseases. RHOA antibodies are immunological tools designed to detect and study RhoA expression, localization, and activity in research or diagnostic contexts.

In cancer, RHOA mutations or altered expression are linked to tumor progression, metastasis, and drug resistance. For example, RHOA hyperactivity is observed in gastric, breast, and lung cancers. Antibodies targeting RhoA help identify its role in oncogenic pathways or tumor microenvironment interactions. In autoimmune diseases like rheumatoid arthritis, aberrant RhoA signaling contributes to inflammation and tissue damage; antibodies aid in mapping these mechanisms.

Therapeutic applications are emerging, with RHOA antibodies explored as biomarkers for disease prognosis or treatment response. Challenges include ensuring specificity due to RhoA's structural similarity to other Rho GTPases and variability in post-translational modifications. Additionally, RHOA antibodies are used in drug development, such as screening inhibitors targeting RhoA-driven pathways.

Overall, RHOA antibodies serve as vital reagents for unraveling RhoA's pathophysiological roles and advancing targeted therapies, though standardization and validation remain critical for clinical translation.